Gemini nanoparticles-based quadruple therapy (GNQT) achieved effective tumor immunotherapy by comprehensive regulation of tumor microenvironment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immune Cell Function and Interaction · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
2. Cancer immunotherapy10.1126/science.342.6165.1432 ↗
3. Cancer immunotherapy comes of age10.1038/nature10673 ↗
4. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy10.1016/j.biomaterials.2022.121794 ↗
5. Improvement of radiotherapy with an ozone-carried liposome nano-system for synergizing cancer immune checkpoint blockade10.1016/j.nantod.2022.101675 ↗
6. Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity10.1016/j.nantod.2022.101377 ↗
7. Immunosuppressive microenvironment improvement and treatment of aggressive malignancy pancreatic ductal adenocarcinoma based on local administration of injectable hydrogel10.1016/j.nantod.2023.101832 ↗
8. Immune checkpoint inhibitors: recent progress and potential biomarkers10.1038/s12276-018-0191-1 ↗
9. Immune checkpoint blockade: a common denominator approach to cancer therapy10.1016/j.ccell.2015.03.001 ↗
10. PD-L1 as a biomarker of response to immune-checkpoint inhibitors10.1038/s41571-021-00473-5 ↗
11. CTLA-4: a moving target in immunotherapy10.1182/blood-2017-06-741033 ↗
12. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
13. In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy10.1016/j.cclet.2020.12.055 ↗
14. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
15. Elements of cancer immunity and the cancer-immune set point10.1038/nature21349 ↗
16. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors10.3390/cancers13020287 ↗
17. Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy10.1126/sciadv.aay1357 ↗
18. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade10.1038/s41419-020-03285-0 ↗
19. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles10.1126/sciadv.abc7828 ↗
20. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase10.1016/j.biomaterials.2018.04.039 ↗
21. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity10.1038/s41577-020-00490-y ↗
22. Coordinated regulation of myeloid cells by tumours10.1038/nri3175 ↗
23. Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer10.1002/adfm.202100715 ↗
24. Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA damage repair pathways and modulating tumor mechanics10.1016/j.nantod.2023.101767 ↗
25. Supramolecular nanofibrils formed by coassembly of clinically approved drugs for tumor photothermal immunotherapy
26. Tumor microenvironment-oriented adaptive nanodrugs based on peptide self-assembly10.1039/D0SC02937H ↗
27. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity10.1016/j.biomaterials.2021.120791 ↗
28. Cooperative self-assembled nanoparticle induces sequential immunogenic cell death and toll-like receptor activation for synergistic chemo-immunotherapy10.1021/acs.nanolett.1c00977 ↗
29. Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy10.1021/acsnano.1c03416 ↗
30. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger10.1016/j.biomaterials.2020.120114 ↗
31. Hyaluronidase with pH‐responsive dextran modification as an adjuvant nanomedicine for enhanced photodynamic‐immunotherapy of cancer10.1002/adfm.201902440 ↗
32. The new era of cancer immunotherapy: Targeting myeloid-derived suppressor cells to overcome immune evasion10.3389/fimmu.2020.01680 ↗
33. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management10.1016/j.pcad.2006.10.002 ↗
34. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy10.1016/j.immuni.2015.11.024 ↗
35. Altered hyaluronan biosynthesis in cancer progression10.1016/j.semcancer.2008.03.006 ↗
36. Therapeutic targeting of hyaluronan in the tumor stroma10.3390/cancers4030873 ↗
37. Hyaluronan and tumor growth10.1016/S0002-9440(10)64232-0 ↗
38. Hyaluronidase to enhance nanoparticle-based photodynamic tumor therapy10.1021/acs.nanolett.6b00068 ↗
39. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators10.1038/s41565-019-0512-0 ↗
40. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells10.1038/s41416-020-0743-8 ↗
41. Myeloid-derived suppressor cells express bruton’s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment10.1158/0008-5472.CAN-15-1490 ↗
42. Distinct migration patterns of naive and effector CD8 T cells in the spleen: correlation with CCR7 receptor expression and chemokine reactivity10.1002/(SICI)1521-4141(199911)29:11<3562::AID-IMMU3562>3.0.CO;2-R ↗
43. Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-α) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis10.1046/j.1365-2249.2001.01439.x ↗
44. Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells10.1111/cei.12392 ↗
45. The association between plasma uric acid and renal function decline in a Chinese population-based cohort10.1093/ndt/gfr597 ↗
46. A role for uric acid in the progression of renal disease10.1097/01.ASN.0000034910.58454.FD ↗
47. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
48. Synthetic helical polypeptide as a gene transfection enhancer10.1021/acs.biomac.2c00331 ↗
49. Metformin booster adipocyte-targeted gene therapy for the treatment of obesity and related metabolic syndromes10.1007/s11426-021-1185-2 ↗
50. Polyglutamic acid based polyanionic shielding system for polycationic gene carriers10.1007/s10118-016-1756-x ↗
51. Cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for potential cancer therapy: preparation, in vitro and in vivo evaluation10.1166/jbn.2016.2152 ↗
52. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo10.1038/s41467-021-27078-x ↗